Allergan Finance LLC 8-K 2010
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 4, 2010
WATSON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Registrants telephone number, including area code: (951) 493-5300
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Item 2.02 Results of Operations and Financial Condition.
On November 4, 2010, Watson Pharmaceuticals, Inc. (the Company) issued a press release reporting the financial results of the Company for the third quarter ended September 30, 2010, and providing a forecast of certain estimated financial metrics for 2010. A copy of the Companys press release is attached to this report as Exhibit 99.1 and incorporated herein by reference.
Additionally, on November 4, 2010, the Company posted on its Investors/Quarterly Results section of its Web site at http://www.watson.com, a table showing adjustments to certain line items of the Companys Statement of Operations to reconcile U.S. generally accepted accounting principles (GAAP) net income to cash net income for the quarterly period ended September 30, 2010. A copy of this table is attached to this report as Exhibit 99.2 and incorporated herein by reference.
Adjusted cash net income and cash earnings per share are supplemental measures of our performance that are not required by, or presented in accordance with, GAAP. We define adjusted cash net income as net income adjusted for amortization, acquisition and licensing charges, global supply chain initiative (including accelerated depreciation charges associated therewith), legal settlements and certain special charges that are otherwise included in GAAP net income, including loss (gain) on asset sales/impairment, loss (gain) on security sales and impairment, loss on debt repurchases and income taxes. Cash earnings per share refers to cash net income divided by the number of diluted shares outstanding.
In its press release and in the quarterly reconciliation table, the Company discloses non-GAAP financial measures (as defined in Regulation G promulgated by the U. S. Securities and Exchange Commission) that exclude certain significant charges or credits that are important to an understanding of the Companys ongoing operations. The Company believes that its inclusion of non-GAAP financial measures provides useful supplementary information to and facilitates analysis by investors in evaluating the Companys performance and trends. The determination of significant charges or credits may not be comparable to similar measures used by other companies and may vary from period to period. The Company uses both GAAP financial measures and the disclosed non-GAAP financial measures internally to evaluate and manage the Companys operations and to better understand its business. These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.
The information in this report (including the exhibits) is furnished pursuant to Item 2.02 and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.